278 related articles for article (PubMed ID: 24107138)
1. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells.
Chen CK; Zhang JZ; Aitken JB; Hambley TW
J Med Chem; 2013 Nov; 56(21):8757-64. PubMed ID: 24107138
[TBL] [Abstract][Full Text] [Related]
2. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological evaluation and SAR studies of novel bicyclic antitumor platinum(IV) complexes.
Lorenzo J; Delgado A; Montaña ÁM; Mesas JM; Alegre MT; Rodríguez Mdel C; Avilés FX
Eur J Med Chem; 2014 Aug; 83():374-88. PubMed ID: 24980119
[TBL] [Abstract][Full Text] [Related]
4. Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity.
Hoffmeister BR; Hejl M; Adib-Razavi MS; Jakupec MA; Galanski M; Keppler BK
Chem Biodivers; 2015 Apr; 12(4):559-74. PubMed ID: 25879501
[TBL] [Abstract][Full Text] [Related]
5. Studies on the photoactivation of two cytotoxic trans,trans,trans-diazidodiaminodihydroxo-Pt(IV) complexes.
Westendorf AF; Bodtke A; Bednarski PJ
Dalton Trans; 2011 May; 40(19):5342-51. PubMed ID: 21461431
[TBL] [Abstract][Full Text] [Related]
6. On the stability and biological behavior of cyclometallated Pt(IV) complexes with halido and aryl ligands in the axial positions.
Escolà A; Crespo M; López C; Quirante J; Jayaraman A; Polat IH; Badía J; Baldomà L; Cascante M
Bioorg Med Chem; 2016 Nov; 24(22):5804-5815. PubMed ID: 27670096
[TBL] [Abstract][Full Text] [Related]
7. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Cytotoxicity and Reactivity of a Novel Platinum(IV) Family with DNA-Targeting Naphthalimide Ligands.
Navas F; Mendes F; Santos I; Navarro-Ranninger C; Cabrera S; Quiroga AG
Inorg Chem; 2017 Jun; 56(11):6175-6183. PubMed ID: 28488859
[TBL] [Abstract][Full Text] [Related]
9. Novel clioquinol and its analogous platinum complexes: importance, role of the halogen substitution and the hydroxyl group of the ligand.
Martín Santos C; Cabrera S; Ríos-Luci C; Padrón JM; López Solera I; Quiroga AG; Medrano MA; Navarro-Ranninger C; Alemán J
Dalton Trans; 2013 Oct; 42(37):13343-8. PubMed ID: 23945635
[TBL] [Abstract][Full Text] [Related]
10. Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent.
Sinisi M; Intini FP; Natile G
Inorg Chem; 2012 Sep; 51(18):9694-704. PubMed ID: 22921246
[TBL] [Abstract][Full Text] [Related]
11. The reduction of cis-platinum(iv) complexes by ascorbate and in whole human blood models using
Chen CKJ; Kappen P; Hambley TW
Metallomics; 2019 Mar; 11(3):686-695. PubMed ID: 30839039
[TBL] [Abstract][Full Text] [Related]
12. trans-Platinum(iv) pro-drugs that exhibit unusual resistance to reduction by endogenous reductants and blood serum but are rapidly activated inside cells:
Chen CKJ; Kappen P; Gibson D; Hambley TW
Dalton Trans; 2020 Jun; 49(23):7722-7736. PubMed ID: 32469362
[TBL] [Abstract][Full Text] [Related]
13. Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design.
Zhang JZ; Bonnitcha P; Wexselblatt E; Klein AV; Najajreh Y; Gibson D; Hambley TW
Chemistry; 2013 Jan; 19(5):1672-6. PubMed ID: 23255183
[TBL] [Abstract][Full Text] [Related]
14. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
Cubo L; Hambley TW; Sanz Miguel PJ; Carnero A; Navarro-Ranninger C; Quiroga AG
Dalton Trans; 2011 Jan; 40(2):344-7. PubMed ID: 20936210
[TBL] [Abstract][Full Text] [Related]
15. A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV).
Kizu R; Nakanishi T; Hayakawa K; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Tashiro T; Kidani Y
Cancer Chemother Pharmacol; 1999; 43(2):97-105. PubMed ID: 9923814
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of series of diazine-bridged dinuclear platinum(II) complexes through in vitro toxicity and molecular modeling: correlation between structure and activity of Pt(II) complexes.
Senerovic L; Zivkovic MD; Veselinovic A; Pavic A; Djuran MI; Rajkovic S; Nikodinovic-Runic J
J Med Chem; 2015 Feb; 58(3):1442-51. PubMed ID: 25551180
[TBL] [Abstract][Full Text] [Related]
17. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
18. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and X-ray crystal structure of trans,cis-[Pt(OAc)2I2(en)]: a novel type of cisplatin analog that can be photolyzed by visible light to DNA-binding and cytotoxic species in vitro.
Kratochwil NA; Zabel M; Range KJ; Bednarski PJ
J Med Chem; 1996 Jun; 39(13):2499-507. PubMed ID: 8691447
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
